全文获取类型
收费全文 | 215015篇 |
免费 | 29342篇 |
国内免费 | 7169篇 |
专业分类
耳鼻咽喉 | 1705篇 |
儿科学 | 1836篇 |
妇产科学 | 5316篇 |
基础医学 | 15456篇 |
口腔科学 | 2162篇 |
临床医学 | 17483篇 |
内科学 | 19980篇 |
皮肤病学 | 1384篇 |
神经病学 | 916篇 |
特种医学 | 6072篇 |
外国民族医学 | 259篇 |
外科学 | 34256篇 |
综合类 | 27439篇 |
现状与发展 | 39篇 |
一般理论 | 3篇 |
预防医学 | 10274篇 |
眼科学 | 116篇 |
药学 | 14967篇 |
140篇 | |
中国医学 | 5062篇 |
肿瘤学 | 86661篇 |
出版年
2024年 | 722篇 |
2023年 | 4546篇 |
2022年 | 8875篇 |
2021年 | 11568篇 |
2020年 | 10851篇 |
2019年 | 9789篇 |
2018年 | 9400篇 |
2017年 | 9877篇 |
2016年 | 10498篇 |
2015年 | 12216篇 |
2014年 | 17642篇 |
2013年 | 17327篇 |
2012年 | 13977篇 |
2011年 | 14338篇 |
2010年 | 10503篇 |
2009年 | 10649篇 |
2008年 | 10870篇 |
2007年 | 10141篇 |
2006年 | 9061篇 |
2005年 | 7392篇 |
2004年 | 6170篇 |
2003年 | 5157篇 |
2002年 | 4374篇 |
2001年 | 3979篇 |
2000年 | 3260篇 |
1999年 | 2746篇 |
1998年 | 2302篇 |
1997年 | 2027篇 |
1996年 | 1622篇 |
1995年 | 1515篇 |
1994年 | 1276篇 |
1993年 | 972篇 |
1992年 | 848篇 |
1991年 | 768篇 |
1990年 | 597篇 |
1989年 | 535篇 |
1988年 | 456篇 |
1987年 | 408篇 |
1986年 | 305篇 |
1985年 | 396篇 |
1984年 | 328篇 |
1983年 | 226篇 |
1982年 | 226篇 |
1981年 | 195篇 |
1980年 | 182篇 |
1979年 | 127篇 |
1978年 | 89篇 |
1977年 | 64篇 |
1976年 | 59篇 |
1975年 | 39篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
《Cancer radiothérapie》2022,26(4):611-615
In order to provide more convenient irradiation regimens for patient comfort, radiation facility organization and health expenses, new hypofractionated protocols have been evaluated. Moderately (dose/fraction: 2.3 to 3 Gy), then ultra (dose/fraction: 5.2 to 6.1 Gy) hypofractionated irradiations were first validated. The current question is: is it possible to go forward using extreme hypofractionated regimens (EHR) based on 1 to 3 fractions. Different irradiation techniques are under investigation. However, brachytherapy remains the smartest way to deliver a high dose in a small volume. We report prospective and retrospective study results which evaluated EHR for breast and prostate brachytherapy. While oncological outcome and toxicity profile appear extremely encouraging for low-risk breast cancer after a 1 to 4 fractions (6.25 to 20 Gy/fraction), the use of a single fraction of 19 to 23 Gy appears debatable for prostate cancer. Brachytherapy represents an emblematic example of EHR but longer follow-up and more mature results are awaited in order to specify the right indications and refine the EQD2 calculation method including new biological and technical factors. 相似文献
2.
《Cancer cell》2022,40(3):318-334.e9
- Download : Download high-res image (268KB)
- Download : Download full-size image
3.
4.
5.
6.
7.
目的探究老年胃癌患者术前血清白细胞介素6 (IL-6)、胃蛋白酶原(PG)Ⅰ、Ⅱ及PG-Ⅰ/Ⅱ比值在患者预后评估中的意义。方法选择2016年1月—2017年1月南通大学附属海安医院收治的101例外科手术治疗的老年胃癌患者为研究对象。收集患者的临床病理资料,检测血清IL-6和PG-Ⅰ/Ⅱ水平。以全因死亡为随访终点,使用Kaplan-Meier曲线明确患者预后与各指标间的关系。结果受试者工作特征曲线提示,IL-6、PG-Ⅰ和PG-Ⅰ/Ⅱ比值在最佳切割值为10.23pg/mL、30.65μg/L和2.44时,可评估患者的预后,而PG-Ⅱ则无法评估患者的预后。与IL-6≤10.23pg/mL组相比,IL-6> 10.23pg/mL组的肿瘤细胞分化更差、TNM分期Ⅲ期比例明显升高。Kaplan-Meier曲线结果表明,IL-6> 10.23pg/mL组的中位生存期显著短于IL-6≤10.23pg/mL组(28个月vs47个月,P<0.001);PG-Ⅰ≤30.65μg/L组的中位生存期显著短于PG-Ⅰ>30.65μg/L组(34个月vs49个月,P=0.008);PG-Ⅰ/Ⅱ≤2.44组的中位生存期显著短于PG-Ⅰ/Ⅱ> 2.44组(29个月vs56个月,P=0.02)。多因素Cox回归分析表明,肿瘤分化程度、TNM分期、IL-6及PG-Ⅰ/Ⅱ比值是影响患者生存率的独立危险因素。结论术前检测IL-6及PG-Ⅰ/Ⅱ比值有助于评估老年胃癌患者的预后。 相似文献
8.
9.
Wuteng Cao Huabin Hu Jiao Li Qianyu Wu Lishuo Shi Biao Li Jie Zhou Xinhua Wang Junhong Chen Chao Wang Huaiming Wang Weihao Deng Yan Huang Yanhong Deng 《International journal of cancer. Journal international du cancer》2023,153(11):1894-1903
Neoadjuvant programmed cell death protein 1 (PD-1) blockade exhibits promising efficacy in patients with mismatch repair deficient (dMMR) colorectal cancer (CRC). However, discrepancies between radiological and histological findings have been reported in the PICC phase II trial (NCT 03926338). Therefore, we strived to discern radiological features associated with pathological complete response (pCR) based on computed tomography (CT) images. Data were obtained from the PICC trial that included 36 tumors from 34 locally advanced dMMR CRC patients, who received neoadjuvant PD-1 blockade for 3 months. Among the 36 tumors, 28 (77.8%) tumors achieved pCR. There were no statistically significant differences in tumor longitudinal diameter, the percentage change in tumor longitudinal diameter from baseline, primary tumor sidedness, clinical stage, extramural venous invasion status, intratumoral calcification, peritumoral fat infiltration, intestinal fistula and tumor necrosis between the pCR and non-pCR tumors. Otherwise, tumors with pCR had smaller posttreatment tumor maximum thickness (median: 10 mm vs 13 mm, P = .004) and higher percentage decrease in tumor maximum thickness from baseline (52.9% vs 21.6%, P = .005) compared to non-pCR tumors. Additionally, a higher proportion of the absence of vascular sign (P = .003, odds ratio [OR] = 25.870 [95% CI, 1.357-493.110]), nodular sign (P < .001, OR = 189.000 [95% CI, 10.464-3413.803]) and extramural enhancement sign (P = .003, OR = 21.667 [2.848-164.830]) was observed in tumors with pCR. In conclusion, these CT-defined radiological features may have the potential to serve as valuable tools for clinicians in identifying patients who have achieved pCR after neoadjuvant PD-1 blockade, particularly in individuals who are willing to adopt a watch-and-wait strategy. 相似文献
10.